Olaparib and Enzalutamide synergistically suppress HCC progression via the AR-mediated miR-146a-5p/BRCA1 signaling
Jie Zhao, Yin Sun, Hui Min Lin, Fu-Ju Chou, Yao Xiao, Renan Jin, Xiujun Cai, Chawnshang Chang
This study shows that combining Olaparib and Enzalutamide synergistically suppresses HCC progression by targeting AR-mediated miR-146a-5p/BRCA1 signaling.
The FASEB Journal · Mar 5, 2020Peer-reviewedSynthetic Biology